Extended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment
What Scientists Paid Attention to in 2025: The 10 Most Read Blog Posts
Drug development is moving fast—and not everything deserves your attention.
Simulations Plus to Participate in Upcoming Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences...
10 Most Read Journal Articles of 2025
In drug development, the science never stands still. Constant research means there is constantly more to know and understand to stay current—but how can you filter through to what is most impactful?
High-Throughput Physiologically Based Pharmacokinetic Model for Rodent Pharmacokinetics Prediction Using Machine Learning-Predicted Inputs and a Large In Vivo Pharmacokinetics Data Set
Accurate prediction of the pharmacokinetic (PK) properties of small-molecule drug candidates is a critical aspect of pharmaceutical research.
Design, Synthesis, and Pharmacological Evaluation of Metabolically Stable Apelin Receptor Antagonists with Improved In Vivo Exposure and Efficacy in Ovarian Cancer
The apelin receptor (APJ) has emerged as a potential novel therapeutic target in cancer due to its role in regulating cell proliferation, angiogenesis, and metastasis.
Investigating the SNAC-To-Drug Ratio for the Oral Absorption of Cyanocobalamin in Rats
The oral route of administration continues to be the preferred and most convenient method for drug delivery among both patients and healthcare professionals.
Novel Descriptors and Models for More Accurate ADME Predictions of Beyond Rule of Five Molecules
This study addresses the critical need for improved physicochemical descriptors and predictive models tailored to beyond Rule of Five (bRo5) compounds, including PROTACs and cyclic peptides. B
Development of a Pregnancy-Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin
Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders.
Clinical Pharmacology Considerations and Modeling of CAR-T Cell Therapies Using Monolix®
Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of hematologic malignancies, delivering durable responses in patients with relapsed and refractory cancers.
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
Showcases platform momentum, strategic priorities, and long-term value creation outlook
Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant
Fezolinetant is a first-in-class, selective, non-hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause.
Fabrication of Second-Generation Acalabrutinib Nanocrystals by Employing the Nano-Edge Method for Improving the Physico-Chemical Properties and Forecasting their In-Silico Pharmacokinetic Behaviour
Acalabrutinib (ACL) is approved by the USFDA and classified as a BCS class II drug, primarily used for treating chronic lymphocytic leukaemia.
Unveiling Anticancer Potential of Imidazo-Pyridine/Pyrazine-Fused bicyclic Heterocycles: Insights From in silico and in vitro Studies
Cancer is a significant global health challenge and the second leading cause of death worldwide, responsible for millions of fatalities annually.
Physiologically Based Pharmacokinetic Model for Clinical Translation and Prediction of Drug Interaction of the Major Kratom Alkaloid, Mitragynine
The opioid crisis presents a significant public health issue and underscores the urgency of developing effective treatments for opioid use disorder (OUD).
Supramolecular Organogels Based on Cinnarizine as a Potential Gastroretentive System: In Vitro and In Silico Simulations
Gastroretentive systems are an interesting option for enhancing the bioavailability of weak bases and poorly soluble drugs.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
Investor Day on January 21, 2026, to present new product vision and AI solutions
How to Streamline Your DMTA Cycle While Being ADMET Aware From the First Iteration
Drug discovery has always been a balancing act, with scientists constantly striving for ‘Goldilocks’ compounds – the search for molecules that achieve on-target activity, while also avoiding hidden liabilities such as toxicity, poor exposure, or unfavorable pharmacokinetics, can seem insurmountable at times.